Clinical Trials Logo
  1. Home
  2. Erosive Esophagitis
  3. NCT05587309

A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis

Erosive Esophagitis Clinical Trial

Official title:
A Phase 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis

Clinical Trial Summary

The objective of the Healing Phase of the study is to evaluate the safety and efficacy of up to 8 weeks of once daily oral administration of BLI5100 versus a PPI control in healing EE. The objective of the Maintenance Phase of the study is to evaluate the safety and efficacy of 24 weeks of once daily oral administration of BLI5100 (low or high dose) versus a PPI control in the maintenance of healed EE.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05587309
Study type Interventional
Source Braintree Laboratories
Contact Leah Hollins
Phone 781-843-2202
Email studydirector@sebelapharma.com
Status Recruiting
Phase Phase 3
Start date October 30, 2022
Completion date December 29, 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT01452776 - Long-Term Safety Study of TAK-438 in the Maintenance Treatment of Healed Erosive Esophagitis Phase 3
Completed NCT04124926 - Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis Phase 3
Completed NCT01459367 - Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Maintenance Treatment of Healed Erosive Esophagitis Phase 3
Completed NCT00228527 - Esomeprazole for Treatment of GERD in Pediatric Patients Phase 4
Completed NCT01499368 - A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients Phase 3
Not yet recruiting NCT04613895 - Treatment Effect According to Timing of Administration of DWP14012 40 mg N/A
Recruiting NCT02615184 - A Study of Dexlansoprazole in Healing and Maintenance of Healed Erosive Esophagitis (EE) in Children Phase 2
Completed NCT02456935 - Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis Phase 3
Completed NCT02028663 - Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis Phase 2
Completed NCT03006874 - Study to Confirm the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis Phase 3
Completed NCT02388724 - Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive Esophagitis Phase 3
Completed NCT01865825 - Proton Pump Inhibitor (PPI) Responsive Eosinophilic Esophagitis EoE: Gastroesophageal Reflux Disease (GERD) or Eosinophilic Esophagitis (EoE)? N/A
Completed NCT02679508 - Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety Phase 4
Recruiting NCT06391177 - A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily Phase 1
Completed NCT05050188 - A Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of Oral Doses of H008 Phase 1
Completed NCT01874535 - Rate of Complete Symptom Relief, Prevention of Symptom Relapse: Grades A and B Esophagitis of Esomeprazole Therapy Phase 4
Completed NCT00206180 - NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis Phase 4
Completed NCT01630746 - A Randomized, Double-Blind, Multicenter Study to Evaluate the Acid-inhibitory and Dose-response Efficacy of TAK-438 (20 mg, 40 mg) in Patients With Proton Pump Inhibitor (PPI) - Resistant Erosive Esophagitis Phase 3
Completed NCT01642615 - Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents Phase 2
Completed NCT01509261 - Efficacy Study of Ilaprazole to Treat Erosive Esophgitis Phase 3